Saturday 17 October 2026
Export ANIP’s income statement to Excel — free account
ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
72.08
0.20
−0.28%
Follow ANIP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
22.55 | 0.00 | 66.50 | 0.00 | 0.00 | 0.00 | 120.92 | 34.11 | 0.00 | 175.06 |
Piotroski F-Score |
7 | 2 | 8 | 5 | 3 | 3 | 5 | 6 | 4 | 5 |
P/S ratio |
1.79 | 1.74 | 2.11 | 2.06 | 2.69 | 1.67 | 3.54 | 2.61 | 4.49 | 5.45 |
Altman Z-Score |
2.30 | 1.43 | 2.42 | 1.40 | 1.23 | 1.35 | 2.75 | 2.09 | 2.79 | 3.57 |
P/FCF ratio |
10.49 | 18.39 | 10.25 | 0.00 | 0.00 | 0.00 | 40.38 | 9.36 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.26 | 1.98 | 3.85 | 2.23 | 2.36 | 1.81 | 3.09 | 1.33 | 2.67 | 2.99 |
Beneish M-Score |
(2.62) | (2.41) | (2.95) | (2.36) | (2.42) | (2.47) | (2.91) | (3.06) | (2.64) | (1.36) |
P/Operating CF |
52.13 | 67.33 | 23.01 | (147.97) | (47.63) | (60.86) | 152.04 | 19.30 | 50.21 | 58.04 |
P/B ratio |
2.93 | 2.65 | 2.38 | 2.08 | 1.74 | 1.78 | 3.43 | 2.67 | 4.54 | 4.13 |
Price to Tangible BV |
0.00 | 0.00 | 5.27 | 19.24 | 48.86 | 96.27 | 25.34 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.16 | 2.51 | 2.25 | 2.80 | 3.55 | 2.52 | 4.13 | 2.74 | 5.45 | 6.18 |
EV/EBITDA |
9.41 | 18.81 | 10.25 | 36.29 | 102.90 | 18.35 | 14.00 | 8.01 | 17.14 | 18.73 |
EV/Operating CF |
10.29 | 24.07 | 9.20 | (28.34) | 231.03 | 34.40 | 18.71 | 8.25 | 24.45 | 28.92 |
EV/FCF |
12.63 | 26.53 | 10.89 | (18.85) | (43.44) | (9.90) | 47.21 | 9.85 | (14.06) | (6.53) |
Quick Ratio |
2.07 | 1.92 | 2.63 | 2.20 | 2.61 | 1.32 | 2.18 | 0.65 | 2.29 | 2.29 |
Current Ratio |
2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 |
Net Debt/EBITDA |
1.59 | 5.77 | 0.60 | 9.57 | 25.08 | 6.21 | 2.02 | 0.40 | 3.03 | 2.20 |
Debt/Assets |
42.84% | 48.59% | 31.59% | 37.70% | 37.24% | 40.26% | 40.66% | 16.38% | 48.89% | 37.37% |
Debt/Equity |
1.14 | 1.46 | 0.62 | 0.85 | 0.80 | 0.95 | 0.87 | 0.36 | 1.15 | 0.71 |
Asset Turnover |
0.65 | 0.56 | 0.58 | 0.41 | 0.35 | 0.45 | 0.47 | 0.48 | 0.48 | 0.42 |
Operating CF/Net income |
2.40 | (3.18) | 6.93 | 0.63 | (0.08) | (0.68) | 7.49 | 4.37 | (36.63) | 7.02 |
Capex/Depreciation |
(0.38) | (0.04) | (0.31) | (0.26) | (0.44) | (1.53) | (0.62) | (0.32) | (3.87) | (6.67) |
Interest Coverage |
5.54 | 0.03 | 1.74 | (1.26) | (3.34) | (1.69) | 1.26 | 2.40 | 2.35 | 1.77 |
| 16.34% | (4.82%) | 4.60% | (15.29%) | (16.16%) | (11.04%) | 2.97% | 8.25% | (0.62%) | 2.37% | |
| 5.66% | (1.84%) | 2.06% | (6.47%) | (6.94%) | (4.91%) | 1.37% | 3.64% | (0.29%) | 1.29% | |
ROIC |
8.05% | 0.04% | 5.62% | (3.86%) | (4.56%) | (2.68%) | 3.04% | 9.83% | 5.13% | 4.77% |
Return on Tangible Assets |
14.36% | (5.15%) | 4.09% | (17.19%) | (14.92%) | (16.95%) | 3.66% | 60.35% | (0.95%) | 4.77% |
Average Days of Receivables |
116.14 | 131.73 | 121.52 | 190.86 | 217.05 | 167.72 | 127.46 | 117.41 | 121.34 | 130.24 |
Research and Development Expense of Revenue |
5.85% | 7.26% | 7.04% | 7.05% | 5.26% | 7.68% | 9.59% | 7.63% | 5.13% | 2.26% |
Selling, General and Administrative Expense of Revenue |
35.97% | 40.63% | 33.22% | 39.21% | 39.00% | 31.17% | 27.04% | 21.86% | 17.86% | 21.64% |
Intangible Assets out of Total Assets |
0.38 | 0.47 | 0.26 | 0.37 | 0.42 | 0.42 | 0.40 | 0.48 | 0.56 | 0.55 |
Share Based Compensation of Revenue |
4.29% | 4.78% | 4.24% | 4.61% | 4.85% | 6.21% | 4.46% | 3.36% | 3.44% | 4.72% |
Graham Net Nets |
(0.09) | (0.31) | 0.07 | (0.12) | (0.16) | (0.27) | (0.08) | (0.15) | (0.13) | (0.07) |
Graham Number |
46.08 | 0.00 | 21.57 | 0.00 | 0.00 | 0.00 | 14.36 | 22.40 | 0.00 | 10.80 |
Earnings Yield |
4.43% | (2.03%) | 1.50% | (7.59%) | (7.06%) | (6.47%) | 0.83% | 2.93% | (0.13%) | 0.57% |
Free Cash Flow Yield |
9.53% | 5.44% | 9.76% | (7.20%) | (3.04%) | (15.27%) | 2.48% | 10.68% | (8.64%) | (17.34%) |
Revenue per Share |
44.05 | 31.80 | 27.04 | 19.46 | 17.16 | 17.43 | 17.44 | 17.26 | 15.32 | 11.24 |
Operating CF per Share |
9.24 | 3.31 | 6.61 | (1.92) | 0.26 | 1.28 | 3.85 | 5.74 | 3.41 | 2.40 |
Capex per Share |
(1.71) | (0.18) | (1.03) | (0.97) | (1.67) | (5.71) | (2.33) | (0.93) | (9.35) | (13.02) |
Free Cash Flow per Share |
7.53 | 3.14 | 5.58 | (2.88) | (1.40) | (4.43) | 1.53 | 4.81 | (5.94) | (10.62) |
Cash per Share |
14.70 | 7.83 | 12.28 | 3.27 | 7.96 | 0.66 | 5.26 | 3.68 | 2.70 | 2.39 |
Shareholders Equity per Share |
26.96 | 22.18 | 25.42 | 20.82 | 28.48 | 16.36 | 17.97 | 16.89 | 15.13 | 14.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
26.96 | 22.18 | 25.42 | 20.82 | 28.48 | 16.36 | 17.97 | 16.89 | 15.13 | 14.82 |
Free Cash Flow |
150.90 | 60.58 | 100.45 | (46.91) | (17.67) | (53.05) | 18.08 | 56.16 | (68.57) | (121.59) |
Working Capital |
475.01 | 334.00 | 374.34 | 244.82 | 234.24 | 91.76 | 126.02 | (12.67) | 92.38 | 71.06 |
Capital Expenditures |
(34.32) | (3.44) | (18.51) | (15.70) | (20.99) | (68.32) | (27.55) | (10.91) | (107.99) | (149.06) |
Net Current Asset Value |
(146.54) | (327.48) | 72.99 | (77.29) | (91.08) | (95.17) | (56.30) | (80.46) | (105.78) | (50.21) |
EV/EBIT |
17.15 | 2,638.34 | 23.29 | 0.00 | 0.00 | 0.00 | 52.21 | 15.65 | 34.03 | 39.57 |
Capex to Sales |
0.04 | 0.01 | 0.04 | 0.05 | 0.10 | 0.33 | 0.13 | 0.05 | 0.61 | 1.16 |
Price to Operating Income |
14.25 | 1,828.59 | 21.92 | 0.00 | 0.00 | 0.00 | 44.66 | 14.87 | 28.01 | 34.92 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.46 | 1.43 | 1.34 | 1.38 | 0.90 | 1.08 | 1.10 | 0.89 | 1.37 | 2.03 |
Cash ROIC |
10.39% | 5.03% | 10.42% | (6.92%) | (2.37%) | (13.63%) | 3.92% | 18.07% | (16.83%) | (38.28%) |
Accounts Receivable Turnover |
3.51 | 3.20 | 2.97 | 2.15 | 1.93 | 2.48 | 3.02 | 3.26 | 3.38 | 3.79 |
Accounts Payable Turnover |
6.31 | 6.08 | 5.50 | 5.31 | 5.88 | 6.74 | 5.38 | 11.67 | 22.52 | 17.88 |
Inventory Turnover |
2.44 | 2.02 | 1.68 | 1.48 | 1.41 | 1.60 | 1.42 | 1.87 | 2.47 | 2.47 |
Average Days of Payables |
66.93 | 66.60 | 73.76 | 77.07 | 83.32 | 47.16 | 84.42 | 44.41 | 16.76 | 25.36 |
Days of Inventory on Hand |
153.00 | 199.53 | 223.60 | 277.08 | 296.37 | 254.63 | 278.36 | 202.45 | 174.24 | 195.92 |
Average Receivables |
251.40 | 191.90 | 163.76 | 146.98 | 112.16 | 83.96 | 68.49 | 61.82 | 52.34 | 33.91 |
Average Payables |
54.12 | 41.17 | 32.99 | 26.14 | 17.11 | 12.93 | 11.75 | 6.26 | 3.51 | 2.73 |
Average Inventory |
139.92 | 123.99 | 108.28 | 93.52 | 71.25 | 54.48 | 44.33 | 39.12 | 31.96 | 19.79 |
Average Assets |
1,362.42 | 1,094.45 | 832.25 | 765.84 | 616.39 | 458.99 | 443.70 | 421.37 | 367.50 | 304.06 |
Average Common Equity |
472.20 | 418.21 | 373.22 | 323.79 | 264.80 | 204.25 | 205.03 | 186.01 | 172.20 | 164.87 |
Columns are period end dates